Immunotherapy and Interactions of Cytokines in the Host

  • K. G. Lundholm
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

A successful outcome from any form of cancer treatment must depend on those features of a tumor which make it distinct in some way from the surrounding normal tissue. In surgery and radiation therapy this aspect is fulfilled by the histological and gross anatomical delineation of tumor tissue. Chemotherapy and immunotherapy are rather dependent on specific or unique features in metabolism, microstructures and on the molecular appearance of tumor cells compared to normal untransformed tissues. However, the lack of adequacy in controlling most malignant tumors demonstrates our present incapacity to define and apply this strategy. Nevertheless, modern medicine and hopefully also cancer treatment will benefit from the rapid development of molecular biology. The purpose of this presentation is to summarize briefly old and recent concepts of immune-interventions in cancer patients and discuss some aspects of continuously expanding research field of cytokines and growth factors in a way that may have a bearing on the clinical horizon.

Keywords

Lymphoma Leukemia Lipase Cortisol Sarcoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hericourt J and Richet CCR: hebd. Seanc. Acad. Sci 1895 (121): 567.Google Scholar
  2. 2.
    Ngu VA: In: Burchenal JH and Burkitt D (eds) Treatment of Burkitt’s Lymphoma. Springer, New York 1967 p 204Google Scholar
  3. 3.
    Nadler SH, Moore GE: Immunotherapy of malignant disease. Arch Surg 1969 (99): 376–381PubMedGoogle Scholar
  4. 4.
    Andrews GA, Congdon CC, Edwards CL, Gengozian N, Nelson B, Vodopick H: Preliminary trials of clinical immunotherapy. Cancer Res 1967 (27): 2535–2541PubMedGoogle Scholar
  5. 5.
    Trouillas P, Lapras C: Cellular immunotherapy of cerebral glioblastoma. A propos of 2 results. J Med Lyon 1969 (50): 1269–1291PubMedGoogle Scholar
  6. 6.
    Yron I, Wood TA, Spiess P, Rosenberg SA: In vitro growth of murine T cells: V The isolation and growth of lymphoid cell infiltrating syngeneic solid tumors. J Immunol 1980 (125): 238–245PubMedGoogle Scholar
  7. 7.
    Lotze MT, Grimme E, Mazumder A, Strausser JL, Rosenberg SA: In vitro growth of cytotoxic human lymphocytes, IV. Lysis of fresh and cultured autologous tumor by lymphocytes cultured in T cell growth factor (TCGF). Cancer Res 1981 (41): 4420–4425PubMedGoogle Scholar
  8. 8.
    Grimm EA, Mazumder A, Zang HZ, Rosenberg SA: The lymphokine activated killer cell phenomenon: Lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982 (155): 1823–1851PubMedCrossRefGoogle Scholar
  9. 9.
    Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA: Lymphokine activated killer cell phenomenon: II The precursor phenotype is serologically distinct from peripherals T lymphocytes, memory CTL, and NK cells. J Exp Med 1983 (157): 884–897PubMedCrossRefGoogle Scholar
  10. 10.
    Rosenstein M, Yron I, Kaufman Y, Rosenberg SA: Lympokine-activated killer cells: Lysis of fresh syngeneic NK-resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res 1984 (44): 1946–1953PubMedGoogle Scholar
  11. 11.
    Mule JJ, Shu S, Schwarz SL, Rosenberg SA: Successful adoptive immunotherapy of established pulmonary metastases with lymphokine-activated killer cells and recombinant interleukin-2. Science 1984 (225): 1487PubMedCrossRefGoogle Scholar
  12. 12.
    Rosenberg SA, Mulé JJ: mmunotheraphy of cancer with lymphokine-activated killer cells and recombinant interleukin-2. Surgery 1985 (98): 437–444PubMedGoogle Scholar
  13. 13.
    Balch CM, Itoh K, Tilden AB: Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor. Surgery 1985 (98): 151–157PubMedGoogle Scholar
  14. 14.
    Grimm EA: Immunotherapy of advanced cancer. N Engl Med 1987 (316): 275–276Google Scholar
  15. 15.
    Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharow S, Seipp C, Custer M, Rosenberg SA: In vivo administration of purified human interleukin-2 II. Half life, Immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 1985 (135): 2865–2875PubMedGoogle Scholar
  16. 16.
    Jacobs SK, Wilson DJ, Kornblith PL, Grimm E: Interleukin-2 or autologous lymphokine-activated cell treatment of malignant glioma:Phase I trial. Cancer Res 1986 (46): 2101–2104PubMedGoogle Scholar
  17. 17.
    Besedovsky H, Del Rey A, Sorkin E, Dinarello CA: Immunoregulatory feedback between interleukin 1 and glucocorticoid hormones. Science (USA) 1986 (233): 652–654Google Scholar
  18. 18.
    Dinarello CA: An update on human interleukin-1: from molecular biology to clinical relevance. J Clin Immunol 1985 (5): 287–297PubMedCrossRefGoogle Scholar
  19. 19.
    Roh MS, Drazenovich KA, Barbose J J, Dinarello CA, Cobb CF: Direct stimulation of the adrenal cortex by interleukin-1. Surgery 1987 (102): 140–146PubMedGoogle Scholar
  20. 20.
    Coombes RC, Rothwell NJ, Shah P, Stock MJ: Changes in thermogenesis and brown fat activity in response to tumour necrosis factor in the rat. Bioscience Reports 1987 (7): 791–799PubMedCrossRefGoogle Scholar
  21. 21.
    Beutler B, Cerami A: Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986 (320): 584–588PubMedCrossRefGoogle Scholar
  22. 22.
    Tracey KJ, Lowry SF, Fahey III TJ, Albert JD, Fong Y, Hesse D, Beutler B, Manogue KR, Calvano S, Wei H, Cerami A, Shires GT: Cachectin-tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 1987 (164): 415–422PubMedGoogle Scholar
  23. 23.
    Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci (USA) 1975 (72): 3666–3670CrossRefGoogle Scholar
  24. 24.
    Haranaki K, Carswell EA, Williamson BD, Prendegast JS, Satomi N, Old LJ: Purification, characterization and antitumour activity of nonrecombinant mouse tumour necrosis factor. Proc Natl Acad Sci (USA) 1986 (83): 3949–3953CrossRefGoogle Scholar
  25. 25.
    Old LJ: Tumor necrosis factor. Scientific American 1988 (25): 41–49Google Scholar
  26. 26.
    Nishimura T, Ohta S, Sato N, Togashi Y, Goto M, Hashimoto Y: Combination tumor-immunotherapy with recombinant tumor necrosis factor and recombinant interleukin 2 in mice. Int J Cancer 1987 (40): 255–261PubMedCrossRefGoogle Scholar
  27. 27.
    Bodel P: Tumours and fever. Ann NY Acad Sci 1974 (230): 6–13PubMedCrossRefGoogle Scholar
  28. 28.
    Coombes RC, Rothwell NJ, Shah P, Stock MJ: Changes in thermogenesis and brown fat activity in response to tumour necrosis factor in the rat. Bioscience Reports 1987 (7): 791–799PubMedCrossRefGoogle Scholar
  29. 29.
    Baumann H, Richards C, Gauldie J: Interaction among hepatocyte-stimulating factors, interleukin-1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (HepG2) cells. J Immunol 1987 (139): 4122–4128PubMedGoogle Scholar
  30. 30.
    Walther Z, May LT, Sehgal PB: Transcriptional regulation of the interferon-B2-B cell differentiation factor BSF-2-Hepatocyte-stimulating factor gene in human fibroblasts by other cytokines. J Immunol 1988 (140): 974–977PubMedGoogle Scholar
  31. 31.
    Moldawer LL, Georgieff M, Lundholm K: Interleukin 1, tumour necrosis factor-alpha (cachectin) and the pathogenesis of cancer cachexia. Clin Physiol 1987 (7): 263–274PubMedCrossRefGoogle Scholar
  32. 32.
    Havell E, Fiers W, North R J: The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 1988 (167): 1067–1085PubMedCrossRefGoogle Scholar
  33. 33.
    North RJ, Havell EA: The antitumor function of tumor necrosis factor (TNF). II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma. J Exp Med 1988 (167): 1086–1099PubMedCrossRefGoogle Scholar
  34. 34.
    Waage A, Espevik T, Lamvik J: Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol 1986 (24): 739–743PubMedCrossRefGoogle Scholar
  35. 35.
    Balkwill F, Osborne R, Burke F, Naylor S, Talbot D, Durbin H, Tavernier J, Fiers W: Evidence for tumour necrosis factor-cachectin production in cancer. Lancet 1987 (2): 1229–1232PubMedCrossRefGoogle Scholar
  36. 36.
    Tracey KJ, Lowry SF, Fahey III TJ, Albert JD, Fong Y, Hesse D, Beutler B, Manogue KR, Calvano S, Wei H, Cerami A, Shires GT: Cachectin-tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 1987 (164): 415–422PubMedGoogle Scholar
  37. 37.
    Sun XM, Hsueh W: Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J Clin Invest 1988 (81): 1328–1331PubMedCrossRefGoogle Scholar
  38. 38.
    Dinarello CA: Interleukin 1. Rev Infect Dis 1984 (6): 51–94PubMedCrossRefGoogle Scholar
  39. 39.
    Hakim AA: Peripheral blood lymphocytes from patients with cancer lack interleukin-2 receptors. Cancer 1988 (61): 689–701PubMedCrossRefGoogle Scholar
  40. 40.
    Ferrua B, Aussel C, Fehlman M: Human interleukin 2. Detection at the picomolar level by sandwich enzyme immunoassay. Journal of Immunological Methods 1987 (97): 215–220PubMedCrossRefGoogle Scholar
  41. 41.
    Lee F, Yokota T, Otsuka T, Meyerson P, Villaret D, Coffman R, Mosmann T, Rennick D, Roehm N, Smith C et al: Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast cell-stimulating activities. Proc Natl Acad Sci USA 1986 (83): 2061–2065PubMedCrossRefGoogle Scholar
  42. 42.
    Hamaguchi Y, Kanakura Y, Fujita J, Takeda S, Nakano T, Tarui S, Honjo T, Kitamura Y: Interleukin 4 as an essential factor for in vitro clonal growth of murine connective tissue-type mast cells. J Exp Med 1987 (165): 268–273PubMedCrossRefGoogle Scholar
  43. 43.
    Campbell HD, Tucker WQJ, Hort Y, Martinson ME, Mayo G, Clutterbuck EJ, Sanderson CJ, Young IG: Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5). Proc Natl Acad Sci USA 1987 (84): 6629–6633PubMedCrossRefGoogle Scholar
  44. 44.
    Koj A, Gordon AH, Gauldie J: An alternative regulatory pathway of the acute phase response: the role of fibroblast-derived interferon-beta 2. Experientia 1988 (44): 9–10PubMedCrossRefGoogle Scholar
  45. 45.
    Hirano T, Yasukawa K, Harada H, Tage T, Yasuo W, Matsuda T, Kishiwamure S, Nakajima K, Koyama K, Wamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T: Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoblobulin. Nature 1986 (324): 73PubMedCrossRefGoogle Scholar
  46. 46.
    Gelin J, Moldawer L, Lonnroth C, DeMan P, Svanborg-Eden C, Lowry S, Lundholm K: Appearence of hybridoma growth factor/interleukin 6 in the serum of cachectic mice bearing a methylcholantrene induced sarcoma. Submitted for publicationGoogle Scholar
  47. 47.
    Goldstein D, Laszlo J: Interferon therapy in cancer: From Imaginon to Interferon. Cancer Res 1986 (46): 4315–4329PubMedGoogle Scholar
  48. 48.
    Aderka D, Levo Y, Ramot B, Michalevicz R, Meytes D, Shaklai M, Hahn T, Holtmann H, Revel M, Wallach D: Reduced production of tumor necrosis factor by mononuclear cells in hairy cell leukemia patients and improvement following interferon therapy. Cancer 1987 (60): 2208–2212PubMedCrossRefGoogle Scholar
  49. 49.
    Einat M, Resnitzky D, Kimchi A: Inhibitory effects of interferon on genes regulated by platlet-derived growth factor. Proc Natl Acad Sci USA 1985 (82): 7608–7612PubMedCrossRefGoogle Scholar
  50. 50.
    Massague J: The TGF-8 family of growth factors and differentiation factors: Minireview. Cell 1987 (49): 437–438PubMedCrossRefGoogle Scholar
  51. 51.
    Sclessinge J, Schreiber A, Levi A, Lax I, Liberman T, Yarden Y: Regulation of cell proliferation by epidermal growth factor. Critical Review in Biochemistry 1983 (14): 93–111CrossRefGoogle Scholar
  52. 52.
    Nickell KA, Halper J, Moses H: Transforming growth factors in solid human malignant neoplasms. Cancer Res 1983 (43): 1966–1971PubMedGoogle Scholar
  53. 53.
    Kimball ES, Bohn WH, Cockley KD, Warren TC, Sherwin SA: Distinct high-performance liquid chromatography pattern of transforming growth factor activity in urine of cancer patients as compared with that of normal individuals. Cancer Res 1984 (44): 3613–3619PubMedGoogle Scholar
  54. 54.
    Sherwin SA, Twardzik DR, Bohn WH, Cockley KC, Todaro GJ: High-molecular-weight transforming growth factor activity in the urine of patients with disseminated cancer. Cancer Res 1983 (43): 403–407PubMedGoogle Scholar
  55. 55.
    Clark SC, Kamen R: The human hematopoietic colony-stimulating factors. Science 1987 (236): 1229–1237PubMedCrossRefGoogle Scholar
  56. 56.
    Morrison SD: Control of food intake in cancer cachexia. A challenge and a tool. Pysiol Behav 1976 (17): 705–714CrossRefGoogle Scholar
  57. 57.
    Moldawer LL, Andersson C, Gelin J, Lundholm KG: Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. Am J Physiol 1988 (254): 450–456Google Scholar
  58. 58.
    McCarthey DO, Kluger MJ, Vander AJ: Suppression of food intake during infection: is interleukin 1 involved? Amer J Clin Nutr 1985 (42): 1179–1182Google Scholar
  59. 59.
    Dinarello CA, Bernheim HA: Ability of human leukocytic pyrogen to stimulate brain prostaglandin synthesis in vitro. J Neurochem 1981 (37): 702–708PubMedCrossRefGoogle Scholar
  60. 60.
    Giulian D, Lachman LB: Interleukin 1 stimulation of astroglial cell proliferation after brain injury. Science (USA) 1985 (228): 497–499Google Scholar
  61. 61.
    Houssiau FA, Bukasa K, Sindic CJM, Van Damme J, Van Snick J: Elevated levels of 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system. Clin Exp Immunol 1988 (71): 320–323PubMedGoogle Scholar
  62. 62.
    Busbridge J, Dascombe MJ, Hoopkins S, Rothwell NJ: Acute central effects of interleukin-6 on body temperature, thermogenesis and food intake in the rat. In press 1988Google Scholar
  63. 63.
    Shimomura K, Manda T, Mukumoto S, Kobayashi K, Nakano K, Mori J: recombinant human tumor necrosis factor-a: Thrombus formation is a cause of anti-tumor activity. Int J Cancer 1988 (41): 243–247PubMedCrossRefGoogle Scholar
  64. 64.
    Baron PL, Lawrence W Jr, Chan WMY, White FKH, Banks WL: Effects of parenteral nutrition on cell cycle kinetics of head and neck cancer. Arch Surg 1986 (121): 1282–1286PubMedCrossRefGoogle Scholar
  65. 65.
    Edström S, Westin T, Delle U, Lundholm K: Cell cycle distribution and ornithine decarboxylase activity in head and neck cancer in response to enteral nutrition. Eur J Cancer Clin Oncol 1988 (in press)Google Scholar
  66. 66.
    Lönnroth C, Moldawer L, Gelin J, Kindblom LG, Mizel B, Lundholm G: Spontaneous interleukin-1 - alpha and cachectin production by tumor cell of cachectic tumor-bearing mice. J. Exper Med. In press 1988Google Scholar
  67. 67.
    Duncombe AS, Gottlieb DJ, Bianchi A, Brenner MK: Bioactivity and immunoreactivity of tumor necrosis factor in cancer patients: letter to the Editor. Lancet 1988 (Januari 30 ): 248Google Scholar
  68. 68.
    Oliff A, DefeoJones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A, Socher SH: Tumors secreting human TNF-cachectin induce cachexia in mice. Cell 1987 (50): 555–563PubMedCrossRefGoogle Scholar
  69. 69.
    Sherry BA, Gelin J, Fong Y, Marano M, Wei H, Cerami A, Lowry S, Lundholm K, Moldawer L: Anticachectin/tumor necrosis factor-alpha antibodies attenuate the development of cachexia in two murine transplantable tumor models. Submitted for publication 1988Google Scholar
  70. 70.
    Yagi MJ, Holland JF, Bekesi JG: Tumor necrosis factor enhances murine SL3-3 retrovirus replication. J Clin Lab Immunol 1987 (24): 129–134PubMedGoogle Scholar
  71. 71.
    Kawakami M, Cerami A: Studies of endotoxin induced decrease in lipoprotein lipase activity. J Exp Med 1981 (154): 631–637PubMedCrossRefGoogle Scholar
  72. 72.
    Baracos V, Rodemann HP, Dinarelk CA, Goldberg AL: Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (Interleukin 1). New Engl J Med 1983 (308): 553–558PubMedCrossRefGoogle Scholar
  73. 73.
    Moldawer LL, Svaninger G, Gelin J, Lundholm K: lnterleukin-1 (alpha or beta) and tumor necrosis factor alpha do not regulate protein balance in skeletal muscle. Am J Physiol 1987 (253): C766–C773PubMedGoogle Scholar
  74. 74.
    Goldberg AL, Kettelhut IC, Furuno K, Fagan JM, Baracos V: Activation of protein breakdown and prostaglandin E2 production in rat skeletal muscle in fever is signaled by a macrophage product distinct from interleukin 1 or other known monokines. J Clin Invest 1988 (81): 1378–1383PubMedCrossRefGoogle Scholar
  75. 75.
    Hill MR, Stith RD, McCallum RE: Interleukin 1: a regulatory role in glucocorticoid regulated hepatic metabolism. J Immunol 1986 (137): 858–862PubMedGoogle Scholar
  76. 76.
    Roh MS, Drazenovich KA, Barbose JJ, Dinarello CA, Cobb CF: Direct stimulation of the adrenal cortex by interleukin-1. Surgery 1987 (102): 140–146PubMedGoogle Scholar
  77. 77.
    Knudsen PJ, Dinarello CA, Strom TB: Glucocorticoids inhibit transcriptional and posttranscriptional expression of interleukin 1 in U937 cells. J Immunol 1987 (139): 4129–4134PubMedGoogle Scholar
  78. 78.
    Mandrup-Poulsen T, Bendtzen K, Dinarello CA, Nerup J: Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta- cell cytotoxicity. J Immunol 1987 (139): 4077–4082PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • K. G. Lundholm
    • 1
  1. 1.Department of Surgery, Sahlgrenska HospitalUniversity of GothenburgSweden

Personalised recommendations